The unexpected uses of urso- and tauroursodeoxycholic acid in the treatment of non-liver diseases
Vang S, Longley K, Steer CJ, Low WC
Published in Global Advances in Health and Medicine
Methodology
Review of clinical and preclinical use of UDCA and TUDCA beyond hepatobiliary disease
Key Findings
Evidence supports cytoprotective effects in neurodegenerative, metabolic and ocular models with limited human trial data
Conclusions
TUDCA shows promise outside liver disease but robust human trials are still needed
Limitations
Narrative review; limited controlled human evidence
Supplements Studied
Outcomes Measured
Cytoprotective effects are supported in neurodegenerative models with limited human data
Herbal antimicrobials achieved breath-test normalisation in 46% of patients compared with 34% for rifaximin
Study Details
Access Study
This information is for educational purposes only. Always consult a healthcare professional before starting any supplement regimen.